In this study, we aim to analyze the effects of elevated CD38 expression and extracellular ADO on different hematological and clinical parameters in mature B-cell lymphoma patients and their link to the soluble counterparts of the PD-1/PD-L1 axis. This evidence concerns the gene CD38 and B-cell non-Hodgkin lymphoma.